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Abstract
Background Despite progress in surgical techniques and
perioperative care, gastrectomy remains a procedure of
signiﬁcant morbidity. Several scoring systems and clinical
measures have been adopted to predict postoperative
complications in gastric cancer patients. The aim of this
study was to investigate whether high serum levels of
interleukin 6 (IL-6) in the early postoperative period may
be a prognostic factor of postoperative morbidity.
Methods A group of 99 consecutive patients with
resectable gastric cancer were enrolled. The mean age was
62.9 years and the male/female ratio was 72:27. Subtotal
gastric resection was performed in 22 patients and total
gastric resection in 77. The IL-6 serum level was measured
on the 1st postoperative day (POD).
Results Complications were recorded in 28 patients
(28.3%).Theobservedcase-fatalityratewas3.03%.AnIL-6
serum level of[288.7 pg/ml on the 1st POD in univariate
and multivariate Cox proportional hazard models was an
independent prognostic factor for overall complications and
infective complications.
Conclusion Our study showed an association between
perioperative IL-6 serum levels and postoperative mor-
bidity in gastric cancer patients. The IL-6 serum level on
the 1st POD was shown to be an independent prognostic
factor for both overall complications and infective
complications.
Keywords Gastric cancer  Postoperative morbidity 
Interleukin 6
Introduction
Postoperative morbidity affects the overall survival, post-
operative mortality, length of hospital stay, and cost of
treatment involved in every major surgical procedure. In
gastric cancer surgery postoperative morbidity remains
high and even if the incidence of gastric cancer declines in
the future this is likely to remain a problem [1]. It is
therefore crucial for both the patient and surgeon to have a
reliable risk assessment model for each major surgical
procedure. For this reason the number of scoring systems
involved in preoperative risk assessment has become
increasingly tailored to speciﬁc groups of patients [2, 3].
Scoring systems predict risk and lead to the imple-
mentation of both prophylactic measures and appropriate
perioperative treatment plans. In the case of gastric cancer,
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disqualiﬁed from surgery due to unacceptably high pre-
operative risk is marginal. Moreover, some risk factors or
risk-generating events are intraoperative. Therefore, a need
has arisen for additional markers or measures that reﬂect
operative injury.
Acute phase proteins (APPs) are deﬁned as those
proteins whose serum concentrations increase or decrease
by at least 25% during inﬂammatory or post-injury states
[4]. Changes in levels of APPs result from the effects of
inﬂammatory mediators, mainly cytokines. Some of the
major cytokines relevant to the acute phase response are
interleukin (IL)-6, IL-1 beta, tumor necrosis factor-alpha
(TNF-a) and interferon gamma. These proteins stimulate
APP production, with IL-6 being the major inducer of
most APPs [5]. This family of cytokines also suppresses
the synthesis of albumin by the liver [6]. On the other
hand, some cytokines (IL-10 and IL-4) suppress the
inﬂammatory reaction. In addition to changes in the
levels of APPs, a number of behavioral, physiologic,
biochemical, and nutritional changes are induced by
inﬂammation-associated cytokines. These include: fever
[7]; neuroendocrine system effects, such as increased
production of corticotropin-releasing hormone [8]; and
anemia of chronic disease [9]. Cytokines, especially IL-6,
are also known to correlate with operative stress and in
some surgical procedures cytokines have been shown to
be reliable markers of postoperative morbidity [10]. IL-6
is a cytokine whose levels rise very early post-surgery
[11].
The aim of this study was to investigate whether high
serum levels of IL-6 in the early postoperative period may
be a prognostic factor of postoperative morbidity.
Methods
A group of 99 consecutive patients with resectable gastric
cancer were enrolled in the study between n March 2005
and September 2006. This study was a cohort study in
which gastric cancer patients were followed up for post-
operative complications.
For the purpose of the study two groups of patients were
created in the post-hoc analysis. Those whose serum IL-6
level was over the 90th percentile in the whole study group
on the 1st postoperative day (POD) were deﬁned as the
‘‘high IL-6 level’’ group, and those whose level was below
the value mentioned were deﬁned as the ‘‘low IL-6 level’’
group.
The cutoff level was arbitrally set because there are no
data in the literature that indicate speciﬁc cutoff values or
allow the creation of ‘‘high level’’ or ‘‘low level’’ groups in
the postoperative period.
There were 27 women and 72 men in our cohort, and the
mean age was 62.9 years (SD 11.2), with ages ranging
between 33 and 86 years. None of the patients selected
underwent preoperative chemotherapy and none had active
infection. All patients were treated with standard postop-
erative care, including enteral nutrition, antimicrobial
prophylaxis for up to 48 h post-surgery, and low-molecu-
lar-weight heparin (LMWH). All complications associated
with each patient were recorded daily, up to the day of
discharge, and thereafter weekly for up to 14 days. Major
and minor complications were integrated in the analysis.
The case-fatality rate was observed up to 30 days. The
average hospital stay was 13.7 days. Tumor staging was
assessed according to the International Union Against
Cancer (UICC) TNM classiﬁcation, 7th edition. The details
of clinicopathological status are summarized in Table 1.
Standard lymphadenectomy for R0 and R1 resections
was D2. In all cases of palliative resections the extent of
lymphadenectomy was at least D1 (11 patients).
Table 1 Patients’ characteristics
N = 99
Gender (n,% )
Women 27 (27.3%)
Men 72 (72.7%)
Age (years)
Mean (SD) 62.9 (11.2)
Min–max 33–86
Stage (n,% )
I 8 (8.1%)
II 22 (22.2%)
III 23 (23.2%)
IV 46 (46.5%)
N = 97
Lauren classiﬁcation (n,% )
Intestinal (1) 36 (37.1%)
Diffuse (2) 60 (60.6%)
Not classiﬁed 1 (1.0%)
Type of surgery (n,% )
Subtotal resection 22 (22.2%)
Total resection 77 (77.8%)
Tumor location (n,% )
Cardia 27 (27.3%)
Other locations 72 (72.7%)
Resection radicality (n,% )
R0 46 (46.5%)
R1 42 (42.4%)
R2 11 (11.1%)
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123Nutritional status was assessed. As the measures of
malnutrition, total albumin level (cutoff \3.5 g/dl), lym-
phocyte count (cutoff\1500/mm
3), and weight loss greater
than 10% of body weight during 6 months were adopted.
Patients were diagnosed as malnourished if two of these
variables were observed.
Concomitant diseases were recorded. Cardiovascular
diseases were observed in 49 patients, respiratory diseases
in 7 patients, diabetes mellitus in 8 patients, and other
chronic comorbidities in 10 patients.
The study was approved by the Institutional Ethics
Commission (Approval number KBET/91/L/2004).
Cytokine assay
Blood samples were collected 16–20 h post closure of the
wound. The blood was centrifuged and serum samples
were stored at -55 C.
For the IL-6 assay the following monoclonal antibodies
were used: IL-6 clone MQ2-13A5 (Capture) and MQ2-
39C3 (Detection); Antibodies were diluted in 0.1 mol
phosphate buffer, pH 9.0, and placed on a 96-well micro-
plate (Nunc Maxisorb, Roskilde, Denmark) according to
the manufacturer’s instructions. The reaction was devel-
oped with biotinylated anti-mouse antibodies. The results
were read using an enzyme-linked immunosorbent assay
(ELISA) microplate reader (Universal Microplate Reader;
Bio-Tek Instruments, Winooski, VT, USA) at the wave-
length of 490/630 nm. The detection range was
10–4030 pg/ml.
Record of complications
The postoperative course was monitored, and all adverse
events were recorded and analyzed. The complication rate
was based upon clinical assessment, imaging studies, and
microbiological examination. Complications were stratiﬁed
into ﬁve groups:
• Infective complications (pneumonia, urinary tract
infections, catheter-related infections, superﬁcial
wound infections)
• Surgical complications (anastomotic/duodenal stump
leakage, intraabdominal bleeding, pancreatic ﬁstula,
wound dehiscence, intestinal obstruction, delayed
wound healing)
• Respiratory complications (pulmonary embolism and
respiratory insufﬁciency, not including pneumonia)
• Cardio-circulatory complications
• Other complications (gastrointestinal [GI] bleeding,
transient pyrexia with negative bacterial cultures and
without clinical signs of infection)
Statistical analysis
The proportion of patients without complications was
presented using Kaplan–Meier curves and the difference
between curves was tested using the log rank test.
To deﬁne patients with ‘‘high’’ IL-6 levels the cutoff
was set at the 90th percentile.
For assessment of the risk of complications the Cox
proportional hazard model was used.
For multivariate analysis, the following covariates were
used: age (B50, 51–60, 61–70, [70 years), stage (I–IV),
Lauren’s type, type of surgery (total or partial resection),
resection radicality, nutritional status, and additionally:
diagnosis of cardiovascular disease (yes/no), diagnosis of
pulmonary disease (yes/no), diagnosis of diabetes (yes/no),
and diagnosis of any other disease (yes/no).
A p level of \0.05 was considered statistically signiﬁ-
cant. Statistical analysis was performed using the STATA
v.8 (StataCorpLP, College Station, TX, USA) software
package.
Results
The number of events and the type of complications were
recorded for each patient. Because one patient could have
more than one complication, the sum of complications
(sum of events) exceeded the number of patients with
complications.
Complications were observed in 28 of the 99 patients
(28.3%) and the observed sum of events was 68 (Table 2).
The most frequent group of complications were infec-
tions, diagnosed in 24.2% of the patients. In this group the
main complication was hospital-acquired pneumonia
(HAP). Among 9 surgical complications there was one case
of anastomotic dehiscence. The perioperative case-fatality
rate was 3.03%—3 patients. These patients died on PODs
8, 14, and 27. All of these patients had been diagnosed with
HAP on PODs four to seven and had no major surgical
complications.
Table 2 Types of complications
Complication type N (%)
Infective 24 (24.2)
Pneumonia 20 (20.2)
Surgical 9 (9.1)
Respiratory (without pneumonia) 5 (5.1)
Cardio-circulatory 4 (4.0)
Other 6 (6.1)
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123IL-6 as a predictor of complications
The 1st POD serum level of IL-6 was analyzed as it was the
earliest postoperative measure available, reﬂecting not only
preoperative factors but also operative injury.
To assess the predictive value of IL-6 serum levels on
the 1st POD a cutoff level of 288.7 pg/ml (the equivalent
of the 90th percentile) was set. Overall complications,
including infective complications, were analyzed 14 days
post-surgery. The proportion of patients without compli-
cations was signiﬁcantly higher in patients with IL-6 levels
below the cutoff value (p = 0.035), and the results were
statistically signiﬁcant (Fig. 1).
The hazard ratio (HR) of complication as an event
assessed in the univariate Cox proportional hazard model
was signiﬁcantly higher in patients with ’’high’’ IL-6 levels
in comparison to those with ‘‘low’’ IL-6 levels (HR = 2.40,
95% conﬁdence interval [CI] 1.05–5.48)—Table 3. The
multivariate analysis produced similar results (HR = 2.79,
95% CI 1.01–7.76) and if the presence of the diagnosis of
other chronic disease was taken into account the risk esti-
mation was even higher (Table 3).
IL-6 on the 1st POD was also analyzed as a potential
predictor of infective complications. The analysis of
Kaplan–Meier curves for the proportion of patients without
infective complications over 14 postoperative days
revealed a trend similar to that seen with overall compli-
cations (Fig. 2). Moreover, these ﬁndings were conﬁrmed
by the univariate and multivariate Cox proportional hazard
models (Table 4).
To avoid the confounding effect of surgical radicality,
anothermodel,withclassiﬁcationR(0,1,2)asoneofpossible
confounding variables, was performed. Risk estimates for
overall complications and infective complications were sim-
ilar to those observed in the previous analyses (Tables 3, 4).
Discussion
Postoperative morbidity in gastric cancer remains high
despite progress in perioperative care and surgical tech-
niques. Gastrectomy for the treatment of gastric cancer is
still one of the major procedures in general surgery and a
30 day postoperative complication rate of 20–40% has
been reported [12–16]. In our study 28.3% of the patients
had major or minor postoperative complications and the
postoperative case-fatality rate was 3.03%. Infections were
the most frequent complication (observed in 24 patients),
which was in line with other studies [3, 17]. However, in
the number of infections reported, some authors included
anastomotic leakage and pancreatic ﬁstulas, as they were
considered the background for secondary infections [18].
Direct comparison of different studies was not always
possible because complication types and data collection
were not uniform [18–20]. The main risk factors reported
in the literature are: the extent of lymphadenectomy,
splenectomy, tumor size, age, comorbidities, American
Society of Anesthesiologists (ASA) score, malnutrition,
and preoperative blood loss [1, 12, 13, 16, 17, 21–23].
Some biochemical measures have also been reported as
predictors of postoperative morbidity. Low serum albumin
and low hemoglobin were reported as negative prognostic
factors for morbidity [2, 22, 23]. These factors reﬂect
malnutrition or the need for perioperative blood transfu-
sions. Increased concentrations of C-reactive protein (CRP)
and procalcitonin corresponded with the risk of postoper-
ative infective complications, especially pneumonia [24].
There is also evidence that elevated pre- or postoperative
levels of cytokines, especially IL-6, may be a prognostic
factor for morbidity in various surgical procedures and
diseases [25–28]. This cytokine is produced rapidly after
surgical trauma and the blood level increases in the hours
post-surgery [11]. On the other hand elevated preoperative
IL-6 levels were observed in patients with more advanced
disease [29]. Other cytokines were sporadically reported as
being associated with the risk of postoperative morbidity.
A postoperative increase in IL-6 was reported in several
studies after stomach resection for gastric cancer [30, 31];
however, its inﬂuence on morbidity was not analyzed. In
assessing the complications of liver surgery, liver trans-
plantation, and cardiothoracic surgery, increased IL-6 lev-
els were indicated as a prognostic factor [25–27].
The postoperative testing of cytokines as well as other
markers seems more rational than preoperative testing of
cytokines concentrations, because the result depends on
Fig. 1 Cumulative proportion of patients without complications
within 14 days post-surgery. IL6 Interleukin 6, POD postoperative
day
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123both tumor-related and patient-related factors and surgery.
The marker should identify patients with an increased
mortality and morbidity risk very early and thus enable
close monitoring, additional diagnostic procedures and
preventive measures, and early treatment of complications
that do arise. Therefore, we investigated IL-6 levels on the
ﬁrst postoperative day (POD). Patients with ‘‘high’’ IL-6
levels had signiﬁcantly higher complication rates. The
univariate analysis calculated the hazard ratio (HR) of
overall complications at 2.4 and that of infective compli-
cations at 2.51. Both estimates were statistically signiﬁcant.
In the Cox proportional hazard model we used covari-
ates (age, stage, Lauren’s type, type of surgery performed,
total albumin level, total lymphocyte count, weight loss,
and the time of weight loss) that might inﬂuence postop-
erative morbidity [21–23]. Finally, the results of our study
showed that a ‘‘high’’ IL-6 level might be an independent
prognostic factor for overall (HR = 2.79) and infective
(HR = 3.07) complications among stomach cancer
patients. When comorbidities and resection radicality were
added to the regression model, the HRs were 3.08 and 3.57,
respectively, both with statistical signiﬁcance.
Our study also has some limitations. IL-6 as a marker of
inﬂammation was observed to be higher among patients
with more advanced disease. The stage of cancer was a
weak predictor of the level of IL-6 in our study and the
correlation coefﬁcient observed for these two variables was
only 0.15. The small sample size prevented us from
Table 3 Risk of overall complications
IL-6 Person-day
(observation)
No. of events/
No. of patients
Risk of
complications (HR)
95% CI p
Overall complications
a 1169
B278.88 pg/ml 19/83 (22.9%) 1
[278.88 pg/ml 8/16 (50.0%) 2.40 1.05–5.48 0.038
Overall complications
b 1046
B278.88 pg/ml 16/74 (21.6%) 1
[278.88 pg/ml 7/14 (50.0%) 2.79 1.01–7.76 0.049
Overall complications
c 1046
B278.88 pg/ml 16/74 (21.6%) 1
[278.88 pg/ml 7/14 (50.0%) 3.08 1.07–8.88 0.038
Overall complications
d 1046
B278.88 pg/ml 16/74 (21.6%) 1
[278.88 pg/ml 7/14 (50.0%) 3.57 1.15–11.10 0.028
IL-6 interleukin 6, HR hazard ratio, CI conﬁdence interval
a Univariate Cox proportional hazard model
b Multivariate Cox proportional hazard model; adjusted for age (B50, 51–60, 61–70,[70), stage (I–IV), Lauren’s type, type of surgery (total or
partial resection), nutritional status (evaluated by total albumin level [cutoff\3.5 g/dl] and total lymphocyte count [cutoff\1500/mm
3]), weight
loss (in kg), and reported time of weight loss (in months)
c Multivariate Cox proportional hazard model; adjusted for age (B50, 51–60, 61–70,[70), stage (I–IV), Lauren’s type, type of surgery (total or
partial resection), nutritional status (evaluated by total albumin level [cutoff\3.5 g/dl] and total lymphocyte count [cutoff\1500/mm
3]), weight
loss (in kg), and reported time of weight loss (in months), diagnosis of cardiovascular disease (yes/no), diagnosis of pulmonary disease (yes/no),
diagnosis of diabetes (yes/no), and diagnosis of any other disease (yes/no)
d Multivariate Cox proportional hazard model; adjusted for age (B50, 51–60, 61–70,[70), stage (I–IV), Lauren’s type, type of surgery (total or
partial resection), nutritional status (evaluated by total albumin level [cutoff\3.5 g/dl] and total lymphocyte count [cutoff\1500/mm
3]), weight
loss (in kg), and reported time of weight loss (in months), diagnosis of cardiovascular disease (yes/no), diagnosis of pulmonary disease (yes/no),
diagnosis of diabetes (yes/no), diagnosis of any other disease (yes/no), and resection radicality (R0, R1, R2)
Fig. 2 Cumulative proportion of patients without infective compli-
cations within 14 days post-surgery
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123performing reliable analysis in the subgroups of stage;
however, stage, Lauren’s type, and type of surgery were
put in the multivariate proportional Cox model as potential
confounders.
A proportion of our patient group underwent palliative
surgery. Among these patients the risk of developing
complications is higher [32]. Resection radicality was also
included in the multivariate analysis. It is still under
question whether the same effect of the high 1st POD IL-6
level on the risk of development of post-surgery compli-
cations may be expected for patients with different R
scores; however, to reveal the answer to this question, more
investigations with large sample sizes are required.
The available data on the possible cutoff for the IL-6
level as a predictor of complications among patients after
stomach cancer surgery are very sparse. In our study we
decided to use the 90th percentile as the threshold; how-
ever, this value characterizes our sample only. More
investigations are needed to evaluate how the proposed
cutoff might be a good predictor of postsurgical compli-
cations for other groups of stomach cancer patients.
It is not clear whether the ‘‘high’’ IL-6 level is metabolic
or whether it is due to an individual property of patients’
immune cells involved in the production of increased
amounts of IL-6. Some investigational data show that IL-6
gene polymorphism may inﬂuence IL-6 serum levels in
vivo [33, 34]. This may result in a high level of IL-6
production that is genetically determined. However, in a
series of cardiosurgery patients this relationship was not
observed [35]. Of note, immunomodulatory strategies have
been adopted to change postoperative cytokine production
and decrease inﬂammatory reactions, to inﬂuence mor-
bidity [36, 37]. These reports describe a limited series of
patients and no large clinical trial in this ﬁeld has been
published.
Conclusion
Our study showed an association between perioperative
IL-6 serum levels and postoperative morbidity in gastric
cancer patients. The ﬁrst POD IL-6 serum level was shown
to be an independent prognostic factor for both overall
complications and infective complications. Therefore, the
results of our study show that the IL-6 serum level could be
used as an early prognostic. The current data on the asso-
ciation of the IL-6 serum level with postoperative mor-
bidity among stomach cancer patients are very limited, and
Table 4 Risk of infective complications
IL-6 Person-day
(observation)
No. of events/
No. of patients
Risk of
complications (HR)
95% CI p
Infective complications
a 1217
B278.88 pg/ml 16/83 (19.3%) 1
[278.88 pg/ml 7/16 (43.8%) 2.51 1.03–6.11 0.042
Infective complications
b 1076
B278.88 pg/ml 14/74 (18.9%) 1
[278.88 pg/ml 7/14 (50.0%) 3.07 1.11–8.43 0.030
Infective complications
c 1076
B278.88 pg/ml 14/74 (18.9%) 1
[278.88 pg/ml 7/14 (50.0%) 3.61 1.23–10.60 0.020
Infective complications
d 1076
B278.88 pg/ml 14/74 (18.9%) 1
[278.88 pg/ml 7/14 (50.0%) 4.35 1.36–13.97 0.013
a Univariate Cox proportional hazard model
b Multivariate Cox proportional hazard model; adjusted for age (B50, 51–60, 61–70,[70), stage (I–IV), Lauren’s type, type of surgery (total or
partial resection), nutritional status (evaluated by total albumin level [cutoff\3.5 g/dl] and total lymphocyte count [cutoff\1500/mm
3]), weight
loss (in kg), and reported time of weight loss (in months)
c Multivariate Cox proportional hazard model; adjusted for age (B50, 51–60, 61–70,[70), stage (I–IV), Lauren’s type, type of surgery (total or
partial resection), nutritional status (evaluated by total albumin level [cutoff\3.5 g/dl), total lymphocyte count [cutoff\1500/mm
3]), weight loss
(in kg) and reported time of weight loss (in months), diagnosis of cardiovascular disease (yes/no), diagnosis of pulmonary disease (yes/no),
diagnosis of diabetes (yes/no), and diagnosis of any other disease (yes/no)
d Multivariate Cox proportional hazard model; adjusted for age (B50, 51–60, 61–70,[70), stage (I–IV), Lauren’s type, type of surgery (total or
partial resection), nutritional status (evaluated by total albumin level [cutoff\3.5 g/dl] and total lymphocyte count [cutoff\1500/mm
3]), weight
loss (in kg) and reported time of weight loss (in months), diagnosis of cardiovascular disease (yes/no), diagnosis of pulmonary disease (yes/no),
diagnosis of diabetes (yes/no), diagnosis of any other disease (yes/no), and resection radicality (R0, R1, R2)
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level. IL-6 levels need to be evaluated prospectively in an
independent group of patients. Moreover, further investi-
gation of the pathogenesis of high IL-6 production and
possible strategies to prevent complications are needed.
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